Literature DB >> 21920759

Allostery in GPCRs: 'MWC' revisited.

Meritxell Canals1, Patrick M Sexton, Arthur Christopoulos.   

Abstract

G protein-coupled receptors (GPCRs) constitute the largest family of receptors in the genome and are the targets for at least 30% of current medicines. In recent years, there has been a dramatic increase in the discovery of allosteric modulators of GPCR activity and a growing appreciation of the diverse modes by which GPCRs can be regulated by both orthosteric and allosteric ligands. Interestingly, some of the contemporary views of GPCR function reflect characteristics that are shared by prototypical allosteric proteins, as encompassed in the classic Monod-Wyman-Changeux (MWC) model initially proposed for enzymes and subsequently extended to other protein families. In this review, we revisit the MWC model in the context of emerging structural, functional and operational data on GPCR allostery.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920759     DOI: 10.1016/j.tibs.2011.08.005

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  23 in total

1.  A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation.

Authors:  Meritxell Canals; J Robert Lane; Adriel Wen; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

Review 2.  Emerging paradigms in GPCR allostery: implications for drug discovery.

Authors:  Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

3.  The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers.

Authors:  Dylan P Kennedy; Fiona M McRobb; Susan A Leonhardt; Michael Purdy; Heidi Figler; Melissa A Marshall; Mahendra Chordia; Robert Figler; Joel Linden; Ruben Abagyan; Mark Yeager
Journal:  Mol Pharmacol       Date:  2013-11-11       Impact factor: 4.436

4.  Na+-mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1.

Authors:  Tetsuya Hori; Toshiaki Okuno; Kunio Hirata; Keitaro Yamashita; Yoshiaki Kawano; Masaki Yamamoto; Masakatsu Hato; Motonao Nakamura; Takao Shimizu; Takehiko Yokomizo; Masashi Miyano; Shigeyuki Yokoyama
Journal:  Nat Chem Biol       Date:  2018-01-08       Impact factor: 15.040

Review 5.  Novel Allosteric Modulators of G Protein-coupled Receptors.

Authors:  Patrick R Gentry; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

6.  Novel selective allosteric and bitopic ligands for the S1P(3) receptor.

Authors:  Euijung Jo; Barun Bhhatarai; Emanuela Repetto; Miguel Guerrero; Sean Riley; Steven J Brown; Yasushi Kohno; Edward Roberts; Stephan C Schürer; Hugh Rosen
Journal:  ACS Chem Biol       Date:  2012-09-14       Impact factor: 5.100

Review 7.  Regulation of G protein-coupled receptors by allosteric ligands.

Authors:  J Robert Lane; Alaa Abdul-Ridha; Meritxell Canals
Journal:  ACS Chem Neurosci       Date:  2013-02-21       Impact factor: 4.418

Review 8.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

Review 9.  Novel GPCR paradigms at the μ-opioid receptor.

Authors:  G L Thompson; E Kelly; A Christopoulos; M Canals
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 10.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.